2021
Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection
McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G, Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J, Villanueva M, Churchwell K, Hsiao A, Torre CJ, Velazquez EJ, Herbst RS, Iwasaki A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. PLOS ONE 2021, 16: e0243291. PMID: 33788846, PMCID: PMC8011821, DOI: 10.1371/journal.pone.0243291.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionYale New Haven HealthSARS-CoV-2Hospital mortalityRisk of admissionMale sexRisk factorsSARS-CoV-2 testingInvasive mechanical ventilationSevere acute respiratory syndrome virusBurden of diseaseRT-PCR testingAcademic health systemDiverse patient populationsRespiratory syndrome virusEthnic groupsAdult patientsClinical characteristicsDischarge dispositionRespiratory supportPrimary outcomeTreatment guidelinesMechanical ventilationRetrospective studyPatient population
2006
Toxicities of Antiangiogenic Therapy in Non–Small-Cell Lung Cancer
Herbst RS. Toxicities of Antiangiogenic Therapy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2006, 8: s23-s30. PMID: 17239287, DOI: 10.3816/clc.2006.s.010.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHumansIndolesLung NeoplasmsNiacinamidePhenylurea CompoundsPiperidinesPyridinesPyrrolesQuinazolinesSorafenibSunitinibVascular Endothelial Growth FactorsConceptsAnti-VEGF antibodyCell lung cancerVascular endothelial growth factorAntiangiogenic agentsOverall survivalLung cancerPhase III pivotal trialsClass-effect toxicitiesFirst-line chemotherapyAdverse event profileSquamous cell histologyChemotherapy-associated toxicityVEGFR tyrosine kinaseTyrosine kinase inhibitorsEndothelial growth factorMetastatic NSCLCThromboembolic eventsCell histologyPivotal trialsEvent profileRisk factorsVEGF receptor activityAntiangiogenic therapySmall molecule inhibitorsTumor typesIndependent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC)
Gandara D, Yoneda K, Shelton D, Beckett L, Ramies D, Bloss J, Herbst R. Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2006, 24: 7071-7071. DOI: 10.1200/jco.2006.24.18_suppl.7071.Peer-Reviewed Original ResearchNon-small cell lung cancerInterstitial lung diseaseFatal interstitial lung diseaseRisk of ILDConcurrent illnessStudy armsEGFR-TKIILD casesRisk factorsProgressive non-small cell lung cancerAdvanced non-small cell lung cancerIncidence of ILDEGFR tyrosine kinase inhibitor therapyTyrosine kinase inhibitor therapyCell lung cancerKinase inhibitor therapyIndependent blinded assessmentConcurrent chemotherapyErlotinib armInhibitor therapyMedical oncologistsSerious complicationsOverall incidenceAsian patientsLung disease
2003
Head and neck cancer
Kies M, Herbst R. Head and neck cancer. 2003, 207-216. DOI: 10.1017/cbo9780511527081.025.Peer-Reviewed Original ResearchSquamous cell cancerNeck malignanciesCell cancerNeck cancerTobacco useNeck squamous cell cancerIndependent risk factorEpstein-Barr virusFloor of mouthConsumption of fruitsDose-response relationshipSynergistic carcinogenic effectUncommon headAdvanced diseaseMost patientsMedian ageAnnual incidenceViral exposureCommon cancerRisk factorsTreatment outcomesIntroduction HeadBuccal mucosaNasopharyngeal carcinomaOral cavity